Vanderbilt research shows that critically ill COVID-19 patients on a mechanical ventilator or extracorporeal membrane oxygenation lived more often when randomized to receive baricitinib.

Two devices for placing a breathing tube during critical illness had similar success rates for intubation on the first attempt, according to a study published Dec. 8 in JAMA.

In a late-stage clinical trial, the biologic agent dupilumab reduced the rate of severe asthma attacks and improved lung function and asthma control for children ages 6 to 11 with moderate-to-severe asthma, offering a new option to these patients.

Clinical trials that focus on specific types of neuroendocrine neoplasms — heterogeneous tumors that can occur anywhere in the body — will be more likely to enhance drug development for these tumors, Vanderbilt physicians assert.